Drugs Made In America Acquisition Rights (DMAAR) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 99 231 sessions, September 8, 2025 to September 10, 2026
- Largest daily move
- +54.5% close of July 21, 2026
- 1-year change
- -29.2% closing prices, September 8, 2025 to September 10, 2026
Company Description
Drugs Made In America Acquisition Rights (NASDAQ: DMAAR) is classified in the blank checks industry.
DMAAR has declined 29.2% over the past year. The last closing price was $0.1274.
For FY2025, Drugs Made In America Acquisition Rights reported net income of $5.9M.
This page collects what Stock Titan holds for DMAAR, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In America Acquisition Rights (DMAAR) closed at $0.1274 on September 10, 2026. Over the past 12 months, the price has lost 29.2%.
DMAAR Metrics & Rankings
Price returns through September 10, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
SEC Filings
Drugs Made In America Acquisition Rights has filed 5 recent SEC filings, including 3 Form SCHEDULE 13G/A, 1 Form 8-K, 1 Form 10-Q. The most recent filing was submitted on September 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMAAR SEC filings →
Financial Highlights
operating income reached -$2.8M, and net income was $5.9M. The company generated -$539K in operating cash flow. With a current ratio of 0.03, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Drugs Made In America Acquisition Rights (DMAAR) currently stands at 174.8 thousand shares, up 125.5% from the previous reporting period. Since September 2025, short interest has increased by 2899.5%.
Days to Cover History
Days to cover for Drugs Made In America Acquisition Rights (DMAAR) currently stands at 3.5 days, down 37.9% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 255% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.0 to 5.7 days.
DMAAR Company Profile & Sector Positioning
Drugs Made In America Acquisition Rights (DMAAR) and is listed on the NASDAQ.